Small organic molecule regulators of cell proliferation

• US 6,613,798 B1
• Filed: 11/28/2000
• Issued: 09/02/2003
• Est. Priority Date: 03/30/2000
• Status: Expired due to Term

• Current Assignee: Curis, Inc.
• Original Assignee: Curis, Inc.
• Inventors: Rubin, Lee, Price, Stephen, Guicherit, Oivin M., Boyd, Edward Andrew, Porter, Jeffrey, Baxter, Anthony David
• Primary Examiner(s): Padmanabhan, Sreeni
• Assistant Examiner(s): JIANG, SHAOJIA A
• Application Number:
  US09/724,955
• Time in Patent Office: 1,008 Days
• Field of Search: 514/183, 514/210, 514/247, 514/395, 514/708, 514/443, 514/444, 514/438, 514/252.01, 514/256, 514/317, 514/319, 514/320
• US Class Current: 514/443
• CPC Class Codes: A61K 31/381 having five-membered rings
• CPC Class Codes: A61K 31/422 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/50 Pyridazines; Hydrogenated pyridazines
• CPC Class Codes: A61K 31/517 ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• CPC Class Codes: C07D 333/70 attached in position 2
• CPC Class Codes: C07D 409/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 409/14 containing three or more hetero rings

Abstract

The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS. 32 and 33. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.

Claims

1. A pharmaceutical preparation comprising a pharmaceutically acceptable excipient and a compound represented in general formula (III):

wherein

Ar and Ar′

independently represent substituted or unsubstituted aryl or heteroaryl rings;

Y, independently for each occurrence, is absent or represents —

NR—

, —

O—

, —

S—

, or —

Se—

;

X is selected from —

C(═

O)—

, —

C(═

S)—

, —

S(O₂)—

, —

S(O)—

, —

C(═

NCN)—

, —

P(═

O)(OR₂)—

, and a methylene group optionally substituted with 1-2 groups selected from lower alkyl, alkenyl, and alkynyl groups;

M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two adjacent M taken together represent substituted or unsubstituted ethene or ethyne;

R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, heteroaralkyl, alkynyl, alkenyl, or alkyl, or two R taken together may form a 4- to 8-membered ring;

Cy and Cy′

independently represent substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;

i represents, independently for each occurrence, an integer from 0 to 5; and

wherein in —

Cy—

Y—

Mi—

NR₂ i is zero and Y is absent.

2. The pharmaceutical preparation of claim 1, wherein Y is absent from all positions.

3. The pharmaceutical preparation of claim 1, wherein M represents, independently for each occurrence, a substituted or unsubstituted methylene group.

4. The pharmaceutical preparation of claim 1, wherein X is selected from —

C(═

O)—

, —

C(═

S)—

, and —

S(O₂)—

.

5. The pharmaceutical preparation of claim 1, wherein NR₂ represents a primary amine or a secondary or tertiary amine substituted with one or two lower alkyl groups, aryl groups, or aralkyl groups.

6. The pharmaceutical preparation of claim 1, wherein Cy′

is a substituted or unsubstituted aryl or heteroaryl.

7. The pharmaceutical preparation of claim 1, wherein Cy′

is bicyclic.

8. The pharmaceutical preparation of claim 7, wherein Cy′

represents a substituted or unsubstituted benzothiophene.

9. The pharmaceutical preparation of claim 8, wherein the benzothiophene ring is substituted with one or more hydrogen, methyl, ethyl, fluorine, chlorine, methoxy, or cyano groups.

10. The pharmaceutical preparation of claim 9, wherein Cy represents a substituted or unsubstituted cyclohexyl.

11. The pharmaceutical preparation of claim 9, wherein each R independently represents H or a lower alkyl.

12. The pharmaceutical preparation of claim 11, wherein NR₂ represents a secondary amine.

13. The pharmaceutical preparation of claim 10, wherein each R independently represents H or a lower alkyl.

14. The pharmaceutical preparation of claim 10, wherein NR₂ represents a secondary amine.

15. The pharmaceutical preparation of claim 11, wherein

i is zero except for M_i between Ar and N;

and all Y are absent.

16. The pharmaceutical preparation of claim 13, wherein

i is zero except for M_i between Ar and N;

and all Y are absent.

17. The pharmaceutical preparation of claim 1, wherein Cy represents a substituted or unsubstituted cyclohexyl group.

18. The pharmaceutical preparation of claim 17, wherein Cy′

represents a substituted or unsubstituted benzothiophene.

19. The pharmaceutical preparation of claim 18, wherein the benzothiophene ring is substituted with one or more hydrogen, methyl, ethyl, fluorine, chlorine, methoxy, or cyano groups.

20. The pharmaceutical preparation of claim 17, wherein each R independently represents H or a lower alkyl.

21. The pharmaceutical preparation of claim 11, wherein NR₂ represents a secondary amine.

22. The pharmaceutical preparation of claim 19, wherein each R independently represents H or a lower alkyl.

23. The pharmaceutical preparation of claim 22, wherein NR₂ represents a secondary amine.

24. The pharmaceutical preparation of claim 20, wherein

i is zero except for M_i between Ar and N;

and all Y are absent.

25. The pharmaceutical preparation of claim 22, wherein

i is zero except for M_i between Ar and N;

and all Y are absent.

26. The pharmaceutical preparation of claim 5, wherein each R independently represents H or a lower alkyl.

27. The pharmaceutical preparation of claim 26, wherein NR₂ represents a secondary amine.

28. The pharmaceutical preparation of claim 26, wherein Cy′

represents a substituted or unsubstituted benzothiophene.

29. The pharmaceutical preparation of claim 28, wherein the benzothiophene ring is substituted with one or more hydrogen, methyl, ethyl, fluorine, chlorine, methoxy, or cyano groups.

30. The pharmaceutical preparation of claim 26, wherein Cy represents a substituted or unsubstituted cyclohexyl group.

31. The pharmaceutical preparation of claim 29, wherein

i is zero except for M_i between Ar and N;

and all Y are absent.

32. The pharmaceutical preparation of claim 30, wherein

i is zero except for M_i between Ar and N;

and all Y are absent.

33. A pharmaceutical preparation comprising a pharmaceutical excipient and a compound represented in general formula (VII):

wherein

Cy represents a substituted or unsubstituted heterocyclyl or cycloalkyl;

Ar is a substituted or unsubstituted aryl or heteroaryl ring;

W is O or S;

R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, heteroaralkyl, alkynyl, alkenyl, or alkyl, or two R taken together may form a 4- to 8-membered ring;

R₁ and R₂ represent, independently and as valency permits, from 0-5 substituents on the ring to which each is attached, selected from halogen, lower alkyl, lower alkenyl, aryl, heteroaryl, carbonyl, thiocarbonyl, ketone, aldehyde, amino, acylamino, amido, amidino, cyano, nitro, hydroxyl, azido, sulfonyl, sulfoxido, sulfate, sulfonate, sulfamoyl, sulfonamido, phosphoryl, phosphonate, phosphinate, —

(CH₂)_palkyl, —

(CH₂)_palkenyl, —

(CH₂)_palkynyl, —

(CH₂)_paryl, —

(CH₂)_paralkyl, —

(CH₂)_pOH, —

(CH₂)_pO-lower alkyl, —

(CH₂)_pO-lower alkenyl, —

O(CH₂)_nR, —

(CH₂)_pSH, —

(CH₂)_pS-lower alkyl, —

(CH₂)_pS-lower alkenyl, —

S(CH₂)_nR, —

(CH₂)_pNR₂, —

(CH₂)_pNR-lower alkyl, —

(CH₂)_pNR-lower alkenyl, —

NR(CH₂)_nR, and protected forms of the above; and

n and p, individually for each occurrence, represent integers from 0 to 10.

34. The pharmaceutical preparation of claim 33, wherein Ar is heteroaryl.

35. The pharmaceutical preparation of claim 33, wherein Ar is bicyclic.

36. The pharmaceutical preparation of claim 33, wherein Cy represents a 5- to 7-membered ring.

37. The pharmaceutical preparation of claim 33, wherein NR₂ represents NH₂.

38. The pharmaceutical preparation of claim 33, wherein Cy includes at least one sp³ hybridized atom.

39. The pharmaceutical preparation of claim 36, wherein Cy represents a substituted or unsubstituted cyclohexyl group.

40. The pharmaceutical preparation of claim 39, wherein Ar represents a substituted or unsubstituted benzothiophene.

41. The pharmaceutical preparation of claim 40, wherein the benzothiophene ring is substituted with one or more hydrogen, methyl, ethyl, fluorine, chlorine, methoxy, or cyano groups.

42. The pharmaceutical preparation of claim 39, wherein each R independently represents H or a lower alkyl group.

43. The pharmaceutical preparation of claim 42, wherein NR₂ represents a secondary amine.

44. The pharmaceutical preparation of claim 40, wherein each R independently represents H or a lower alkyl group.

45. The pharmaceutical preparation of claim 44, wherein NR₂ represents a secondary amine.

46. The pharmaceutical preparation of claim 35, wherein Ar represents a substituted or unsubstituted benzothiophene.

47. The pharmaceutical preparation of claim 46, wherein the benzothiophene ring is substituted with one or more hydrogen, methyl, ethyl, fluorine, chlorine, methoxy, or cyano groups.

48. The pharmaceutical preparation of claims 47, wherein Cy represents a substituted or unsubstituted cyclohexyl group.

49. The pharmaceutical preparation of claim 47, wherein each R independently represents H or a lower alkyl group.

50. The pharmaceutical preparation of claim 49, wherein NR₂ represents a secondary amine.

51. The pharmaceutical preparation of claim 48, wherein each R independently represents H or a lower alkyl group.

52. The pharmaceutical preparation of claim 51, wherein each NR₂ represents a secondary amine.

53. The pharmaceutical preparation of claim 33, wherein each R independently represents H or a lower alkyl group.

54. The pharmaceutical preparation of claim 53, wherein NR₂ represents a secondary amine.

55. The pharmaceutical preparation of claim 53, wherein Cy represents a substituted or unsubstituted cyclohexyl group.

56. The pharmaceutical preparation of claim 53, wherein Ar represents a substituted or unsubstituted benzothiophene.

57. The pharmaceutical preparation of claim 55, wherein Ar represents a substituted or unsubstituted benzothiophene.

58. The pharmaceutical preparation of claim 56, wherein the benzothiophene ring is substituted with one or more hydrogen, methyl, ethyl, fluorine, chlorine, methoxy, or cyano groups.

59. The pharmaceutical preparation of claim 57, wherein the benzothiophene ring is substituted with one or more hydrogen, methyl, ethyl, fluorine, chlorine, methoxy, or cyano groups.